The University of Texas MD Anderson Cancer Center
Aman U. Buzdar mostly deals with Breast cancer, Internal medicine, Tamoxifen, Anastrozole and Oncology. His Breast cancer study frequently links to related topics such as Surgery. Adjuvant therapy is the focus of his Internal medicine research.
His Exemestane study, which is part of a larger body of work in Tamoxifen, is frequently linked to Population, bridging the gap between disciplines. His study brings together the fields of Cancer and Oncology. His Gynecology research integrates issues from Tolerability and Randomized controlled trial.
His primary areas of investigation include Internal medicine, Oncology, Breast cancer, Chemotherapy and Tamoxifen. The various areas that Aman U. Buzdar examines in his Internal medicine study include Gynecology and Surgery. His Oncology research incorporates themes from Epirubicin, Estrogen receptor, Disease and Docetaxel.
His work carried out in the field of Breast cancer brings together such families of science as Stage, Regimen, Randomized controlled trial and Adjuvant therapy. His Chemotherapy research is multidisciplinary, incorporating perspectives in Primary tumor, Metastasis, Metastatic breast cancer and Radiation therapy. He interconnects Exemestane and Advanced breast in the investigation of issues within Anastrozole.
Internal medicine, Breast cancer, Oncology, Anastrozole and Cancer are his primary areas of study. His study in the fields of Tamoxifen, Epirubicin and Meta-analysis under the domain of Internal medicine overlaps with other disciplines such as Single-nucleotide polymorphism and Hazard ratio. His Epirubicin research includes themes of Gynecology and Trastuzumab.
His Oncology research incorporates elements of Immunohistochemistry, Randomization and Pertuzumab. Aman U. Buzdar combines subjects such as Log-rank test, Cyclophosphamide and Median follow-up with his study of Randomization. The various areas that Aman U. Buzdar examines in his Pertuzumab study include Regimen, Lapatinib and Chemotherapy.
His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Anastrozole and Single-nucleotide polymorphism. His research on Breast cancer focuses in particular on Epirubicin. His studies deal with areas such as Log-rank test, Gynecology, Trastuzumab and Randomization as well as Epirubicin.
The concepts of his Randomization study are interwoven with issues in Cancer and Median follow-up. Aman U. Buzdar integrates Single-nucleotide polymorphism and Affect in his research. His Residual risk research is multidisciplinary, relying on both Tamoxifen, Clinical endpoint, Receptor and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe;R. Abe;K. Enomoto;K. Kikuchi.
The Lancet (2005)
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
C Focan;SM Steinberg;M Blichert-Toft;JF Forbes.
The Lancet (1998)
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
J. M. Nabholtz;A. Buzdar;M. Pollak;W. Harwin.
Journal of Clinical Oncology (2000)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
M Baum;A Buzdar;J Cuzick;J Forbes.
Breast carcinoma in men: a population-based study.
Sharon H. Giordano;Deborah S. Cohen;Aman U. Buzdar;George Perkins.
Is breast cancer survival improving
Sharon H. Giordano;Aman U. Buzdar;Terry L. Smith;Shu Wan Kau.
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
Valentina Guarneri;Kristine Broglio;Shu Wan Kau;Massimo Cristofanilli.
Journal of Clinical Oncology (2006)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Buzdar A;Howell A;Cuzick J.
Lancet Oncology (2006)
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Aman Buzdar;Walter Jonat;Anthony Howell;Stephen E. Jones.
Journal of Clinical Oncology (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: